The final, formatted version of the article will be published soon.
SYSTEMATIC REVIEW article
Front. Oncol.
Sec. Gastrointestinal Cancers: Hepato Pancreatic Biliary Cancers
Volume 14 - 2024 |
doi: 10.3389/fonc.2024.1483521
This article is part of the Research Topic Liver Cancer Awareness Month 2024: Current Progress and Future Prospects on Advances in Primary Liver Cancer Investigation and Treatment View all 6 articles
Diagnosis of Hepatocellular Carcinoma Using Liquid Biopsy-Based Biomarkers: A Systematic Review and Network Meta-Analysis
Provisionally accepted
Yutong Jiang
1,2
Shangwen Qi
1,2
Rongrong Zhang
1,2
Ruixia Zhao
1
Yu Fu
1
Yuxuan Fang
1,2*
Mingyi Shao
1*- 1 The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, China
- 2 The First Clinical Medical College of Henan University of Chinese Medicine, Zhengzhou, China
The diagnostic performance of liquid biopsy-based biomarkers for HCC was comprehensively compared in this network meta-analysis (NMA). A thorough literature search was conducted to identify all comparative studies from January 1, 2000, to January 11, 2024. The QUADAS-2 tool was utilized to appraise the quality of studies involving diagnostic performance. R (v4.3.3) and an ANOVA model-based NMA were used to assess the diagnostic accuracy of each biomarker. This study included 82 studies comprising a total of 15,024 patients. CircRNA demonstrated significantly superior performance in distinguishing HCC from healthy populations (superiority index: 3.550 (95% CI [0.143-3])) compared to other diagnostic biomarkers for HCC. "mRNA exhibited significantly superior performance in distinguishing HCC from liver disease patients (superiority index: 10.621 (95% CI [7-11])) compared to other diagnostic biomarkers for HCC. Further subgroup analysis of the top-ranking liquid biopsy-based diagnostic biomarkers revealed that hsa_circ_000224 (superiority index: 3.091 (95% CI [0.143-9]) ranked remarkably higher in distinguishing HCC from both healthy populations and liver disease patients. Subgroup analysis of mRNA demonstrated that KIAA0101 mRNA (superiority index: 2.434 (95% CI [0.2-5]) ranked remarkably higher in distinguishing HCC from healthy populations and liver disease patients, respectively. The results of this meta-analysis show that circRNA and mRNA are the first choice for HCC diagnosis. Subsequent analysis of circRNA and mRNA highlighted hsa_circ_000224, hsa_circ_0003998, KIAA0101 mRNA and GPC-3 mRNA as the optimal diagnostic biomarkers for distinguishing HCC from healthy populations and liver disease patients, respectively. Well-structured prospective studies are crucial to comprehensively validate these findings.
Keywords: Hepatocellular Carcinoma, liquid biopsy, diagnostic biomarkers, Network meta-analysis, Liver disease
Received: 20 Aug 2024; Accepted: 31 Dec 2024.
Copyright: © 2024 Jiang, Qi, Zhang, Zhao, Fu, Fang and Shao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Yuxuan Fang, The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, China
Mingyi Shao, The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.